poisar

Stock

Caribou Biosciences, Inc. CRBU

$0.34-1.66%

Overview

CRBU market data

Business OverviewA provider-written description of this company or fund, with its source and observation date.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Official website

Source
massive
Observed
Cadence
Reference data reviewed periodically
Status
fresh

Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.

CRBU price chart · 1M
O
0.337400
H
0.345000
L
0.335100
C
0.337100
Vol
3,871.00

Daily history from Jul 23, 2021

Source
US equities market feed
Observed
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.

Open
$0.34
Previous Close
$0.34
Day High
$0.35
Day Low
$0.34
52 Week High
$2.49
52 Week Low
$0.33
7 Day Return
-13.59%
30 Day Return
-28.15%
90 Day Return
-78.93%
1 Year Return
-82.02%
Daily Notional Volume
$1.3K
Latest daily bar volume multiplied by its closing price.

Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.

Provider-backed
P/E (TTM)
—
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
—
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.59
Diluted earnings per share over the trailing twelve months.
Beta
2.64
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
—
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-1,085.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.36 – $2.49
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
—
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $36.8M · P/B 1.22 · P/S 3.90.

Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.

10 captured

Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock

AI-selected reference, checked against source evidence · Evidence observed

Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.

What business does Caribou Biosciences, Inc. operate?
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Which industry is Caribou Biosciences, Inc. classified in?
The SEC company record classifies Caribou Biosciences, Inc. under Biological Products, (No Diagnostic Substances). This filing classification provides industry context alongside the provider's business description.

What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.

  • Business activities described in the company reference
  • Original company disclosures and industry classification